CA-CONVIVA
28.4.2022 19:55:06 CEST | Business Wire | Press release
Conviva , the continuous measurement analytics platform for streaming media, released its third annual TikTok Benchmarks & Strategy Guide today, examining more than 1500 verified brand accounts on TikTok, with a combined 1.42 billion followers and 591,000 posted videos. The report details which brands are most effectively capitalizing on the pandemic-fueled increased popularity of TikTok and highlights how the most successful brands were able to add an average of 527,000 new followers from March 2021 to March 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006098/en/
“At the beginning of the pandemic, many brands were still hesitant to fully embrace TikTok as a powerful tool in their marketing strategy. However, over the last 18 months TikTok’s growth and popularity has exploded—and brands are racing to build and execute a strategy to tap into this massive incremental audience,” said Nick Cicero, VP of Strategy, Conviva. “With no signs of slowing down, it’s important for brands to understand what tactics—namely consistently posting quality content—actually move the needle in terms of engagement and brand building on TikTok.”
Across the industries measured by Conviva, sports leagues’ accounts achieved the largest average annual increase of followers at 969,800, followed by sports media at 825,000. Four TikTok accounts—Tottenham Hotspur, Champions League, Manchester United and Netflix—all increased their following by more than 10 million followers in the last year. ESPN was close behind with an increase of 9.1 million followers. Sports leagues also edged out sports media accounts to become the fastest growing segment of 2021.
As many brands have come to realize in the last year, Conviva’s research shows that posting consistently makes a significant difference when building a TikTok following. Of the 1500 brand accounts measured, accounts posted, on average, 189 times in the past year, a 13% increase from last year’s average. Additionally, among the top 20 accounts ranked by follower growth, those accounts averaged roughly 7.1 times more posts over the past year than all accounts, on average. For top performers, that amounts to around three to four posts per day, up from two to three times per day from last year’s report.
Recognizing that engagement has become an important metric for brands, Conviva added an average engagement rate ranking to this year’s report. According to Conviva data, the average engagement rate for brands with under 100,000 followers is incredibly high at 28%, demonstrating TikTok’s well-honed ability to offer new accounts the organic reach they need to build a following. However, as follower counts go up, engagement rates typically go down. For example, Family Feud, an account notoriously popular for its reshared audio tracks, took the top spot for accounts with over 1 million followers with an engagement rate of 41.6%.
Other findings include:
- Of the nine sports leagues analyzed, teams in the Premier League had the highest average number of followers at 3.2 million, followed by Ligue 1 at 2.1 million and La Liga at 1.7 million. European futbol teams dominated the fastest growing accounts list with eight European teams in the top 20.
- The most-followed US sports teams were the Golden State Warriors at 3.7 million, the Kansas City Chiefs at 2 million and Dallas Cowboys at 1.7m. The Chiefs, Cowboys and the Warriors were the only American teams in the top 25.
- Guinness World Records maintained its spot at the top of the brands list with 19.1 million followers.
- Overall, engagement rate rankings were dominated by TV and entertainment accounts. Those accounts enjoyed the highest average shares, comments and likes per video.
- Within the brands ranking, gaming showed up big this year as Roblox and Fortnite claimed the No. 2 and 3 spots at 7.9 million and 7.7 million, respectively.
- WWE overtook NBA as the most-followed sports league.
In addition to offering the latest benchmark data, Conviva also shares specific forward-looking trends to employ to achieve TikTok success in 2022. Businesses interested in utilizing these strategies and learning more about emerging social media platforms can download Conviva’s TikTok Benchmarks & Strategy Guide here: https://www.conviva.com/state-of-streaming/convivas-2022-tiktok-benchmarks-strategy-guide-for-brands
About Conviva Social Insights
Conviva Social Insights provides the world’s leading publishers, brands and sports organizations with comprehensive cross-platform social media analytics across the entire social universe (Facebook, Instagram, Twitter, TikTok, Snapchat and YouTube), making it easy to discover what accounts, posts, and videos are performing the best and analyze why. Social Insights also offers a customizable leaderboard and research tool for monitoring the performance of brand and streamed videos, enabling marketers to target campaigns and maximize ROI. To learn more, visit https://www.conviva.com/social-insights/ .
About Conviva
Conviva helps streaming businesses act within seconds of observation to grow their business ahead of competition. Conviva’s Continuous Measurement Analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, our 58 patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006098/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
